Article · Wikipedia archive · Last revised Jun 25, 2026

AB0124

AB0124 is a serotonin 5-HT2A receptor positive allosteric modulator. It is highly selective for potentiation of the serotonin 5-HT2A receptor, with no potentiation of the serotonin 5-HT2B and 5-HT2C receptors. In addition, it showed no orthosteric agonistic activity at any of the serotonin 5-HT2 receptors. AB0124 has been studied in combination with the serotonin 5-HT2 receptor agonist (R)-DOI in animal models of cocaine use disorder. The chemical synthesis of AB0124 has been described. The drug was patented in 2022 and was first described in the scientific literature by 2024.

Last revised
Jun 25, 2026
Read time
≈ 1 min
Length
321 w
Citations
12
Source
Wikipedia ↗
AB0124
Clinical data
Other namesAB-0124; ABO124; ABO-124
Drug classSerotonin 5-HT2A receptor positive allosteric modulator
Identifiers
  • N-[2-(dimethylamino)ethyl]-4-(2-phenylethyl)piperidine-2-carboxamide
PubChem CID
Chemical and physical data
FormulaC18H29N3O
Molar mass303.450 g·mol−1
3D model (JSmol)
  • CN(C)CCNC(=O)C1CC(CCN1)CCC2=CC=CC=C2
  • InChI=1S/C18H29N3O/c1-21(2)13-12-20-18(22)17-14-16(10-11-19-17)9-8-15-6-4-3-5-7-15/h3-7,16-17,19H,8-14H2,1-2H3,(H,20,22)
  • Key:YAFSEZSVGMQXTE-UHFFFAOYSA-N

AB0124 is a serotonin 5-HT2A receptor positive allosteric modulator.123 It is highly selective for potentiation of the serotonin 5-HT2A receptor, with no potentiation of the serotonin 5-HT2B and 5-HT2C receptors.12 In addition, it showed no orthosteric agonistic activity at any of the serotonin 5-HT2 receptors.1 AB0124 has been studied in combination with the serotonin 5-HT2 receptor agonist (R)-DOI in animal models of cocaine use disorder.21 The chemical synthesis of AB0124 has been described.3 The drug was patented in 20223 and was first described in the scientific literature by 2024.21

See also

See also

References

References

  1. Merritt RF, Anastasio N, Zhou J, Cunningham K (January 2026). "ACNP 64th Annual Meeting: Poster Abstracts P292-583". Neuropsychopharmacology. 51 (Suppl 1): 243–409. doi:10.1038/s41386-025-02280-3. PMC 12783661. PMID 41507445.
  2. Bolinger AA, Zamora J, Merritt CR, Anastasio NC, Cunningham KA, Zhou J (March 2024). Discovery of novel serotonin 5-HT2A receptor positive allosteric modulators (PDF). 16TH Annual Behavior, Biology, and Chemistry: Translational Research in Substance Use Disorders, San Antonio, Texas | Embassy Landmark | 22-24 March 2024. Synthesizing and screening novel small molecules, we identified potent positive allosteric modulators (PAMs) of 5-HT2AR. Further analysis and comparison against CNS receptors, channels, and transporters led to the identification of AB0124 a potential candidate with high specificity. This compound has demonstrated functional increases in 5-HT-induced Ca2+ release at the micromolar level for the 5-HT2AR over other serotonin receptors. With promising in vitro pharmacological and physicochemical profiles, our novel 5-HT2AR PAMs hold potential as neurotherapeutics for [cocaine use disorder (CUD)].
  3. WO 2023/023287A1, Zhou J, Cunningham KA, Bolinger AA, Anastasio NC, "Novel heterocyclic compounds as serotonin (5-ht) 5-ht2a and 5-ht2c receptor positive allosteric modulators", issued 23 February 2023, assigned to University of Texas System, University of Texas at Austin